Global beta glucan and fucoidan market is projected to grow at a CAGR of 8.08% during the forecast period (2020-2025)
- The growing application of beta-glucan and fucoidan in nutraceutical supplements is majorly driving the market growth across the globe. Evolved consumer trends and rising demand for immunity booster foods and diets have created lucrative opportunities for both ingredients, with the potential to grow rapidly during the coming years. - Furthermore, improving the extraction techniques for microalgae cultivation will allow manufacturers to make effective use of beta glucan microalgae in the food, dietary supplements, and healthcare industries, among others. In this regard, numerous efforts are being carried out by several organizations. These aforementioned factors are expected to contribute to the overall growth of the market during the forecast period.
Key Market Trends GROWING EXPANSION IN IMMUNITY INGREDIENT SPACE
During the last decade, the immunity health segment has been witnessing an inflow of numerous novel and functional ingredients targeted toward specific health needs. From classical ingredients, such as vitamins and botanicals, the market is now shifting toward the use of ocean’s seaweed, such as fucoidan and yeasts’ beta glucans, to continue to diversify and expand the market.
In line with this, beta glucan, which is characterized as the most popular emerging ingredient in the immunity health segment, is witnessing huge demand from consumers globally. Yeast beta-glucan is derived from baker’s yeast, and is found to maintain or stimulate the effectiveness of the immune system.
Additionally, fucoidan extracts have been found to ameliorate acute colitis, have anti-cancer Activity mediate via natural killer (NK) cells, and affect inflammation, vascular physiology, as well as oxidative stress.
Asia-Pacific Region to Witness Fastest Growth
In Asia-Pacific region, China and Japan hold significant shares and expected to dominate the market during the forecast period. The application of beta glucan in the infant formula products in China has been witnessing significant growth for the past couple of years, owing to the increasing demand and growing unit prices. After the two-child policy was officially executed in October 2015, the new-born population increased, which has been strengthening the need for infant formula and immunity-boosting ingredients in the various forms of food beverage and nutraceutical product from 2017, which has been driving the beta-glucan and fucoidan market.
IN Japan, there has been an increase in the demand for beta-glucan and fucoidan for nutraceutical and pharmaceutical applications, as Japan has a continually aging population. In 2018, 28% of the population was aged over 65 years, up from 22% from 2008, which is supporting the demand for dietary supplements in the country.
In 2015, a regulatory body, “Foods with Functional Claims (FFC)”, was introduced in Japan. This classification allows specific health claims to be made about products. It had a positive impact on the performance of dietary supplements, especially with soluble fiber, like beta-glucan, toward the end of the review period.
Competitive Landscape The global beta-glucan and fucoidan market is highly fragmented, particularly with the significant presence of numerous global and regional players. The global beta-glucan market is dominated by the players, such as Lantmännen and DSM, among others.
The beta-glucan ingredients market is witnessing a high level of competition among the leading players mentioned above for maximizing the prominence in the market. The companies, such as Lantmännen, expanded the production facility for beta-glucan ingredients to cater to the rising demand in the Swedish market in the food and beverage and other industries.
The global fucoidan market is dominated by key players, such as Sigma Aldrich (owned by Merck KGaA), Yaizu Suisankagaku Industry Co. Ltd, Marinova, and Vesta Ingredients Inc.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - 3 months of analyst support
Our reports have been used by over 10K customers, including:
263 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer...
The oncology information systems market is projected to reach USD 9.5 billion by 2025 from USD 6.7 billion in 2020, at a CAGR of 7.4% during the forecast period. Growth of the market is mainly attributed to the technological advancements; increasing incidences of cancer cases, and growing public and private investments, funding, and grants...
74 pages •
By Asia Market Information & Development Company
• Apr 2021
This study focuses on China’s Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China...
138 pages •
By Asia Market Information & Development Company
• Apr 2021
This study focuses on China’s Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s...
The global cold plasma equipment market is expected to reach US$ 308.87 Mn in 2027 from US$ 96.67 Mn in 2019. The market is estimated to grow with a CAGR of 15.6% from 2020-2027. The growth of the cold plasma equipment market is primarily attributed to the factors such as increasing use of cold plasma in medical treatment, increasing...
442 pages •
By The Business Research Company
• Nov 2020
Oncology Drugs Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global oncology drugs market. Description: Where is the largest and fastest growing market for the oncology...
The global cold plasma equipment market is expected to reach US$ 308.14 Mn in 2027 from US$ 96.67 Mn in 2019. The market is estimated to grow with a CAGR of 15.7% from 2020-2027. The growth of the cold plasma equipment market is primarily attributed to the factors such as increasing use of cold plasma in medical treatment, increasing hospital...
The global generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027. Factors such as, growing cancer prevalence across the globe, new product launches and benefits offered by generic drugs are boosting the market over the years....
Market Overview Growing prevalence of cancer is one of the major factors for the growth of the global Cryotherapy market. As per the WHO statistics, cancer accounts for 13% of deaths globally every year, moreover, 70% increase in cancer incidences is anticipated over the next couple of decades and global geriatric population...
The global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025. The growth of the pancreatic cancer therapy market is primarily attributed to the increase in number of therapies launched in the market.The development...
Oncology
World
APAC
Health Expenditure
Cancer Incidence
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.